APO Research
Talk to an analyst

APO RESEARCH · REPORT

Orally Administered Vaccine

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Orally Administered Vaccine Industry Growth and Trends Forecast to 2032

20 December 2025111 pages

Choose your research edition.

Industry ResearchOrally Administered Vaccine Industry Research Report 2026135 pages · $2,950 USDIndustry Growth & TrendsGlobal Orally Administered Vaccine Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Orally Administered Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Orally Administered Vaccine Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Orally Administered Vaccine Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Orally Administered Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Orally Administered Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Orally Administered Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Orally Administered Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Orally Administered Vaccine include Lanzhou Institute, Sanofi, Merck, GSK, Tiantan Biological, Valneva, Vabiotech, Shanghai United Cell and Serum Institute, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Orally Administered Vaccine market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Orally Administered Vaccine market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Orally Administered Vaccine market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Orally Administered Vaccine.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Orally Administered Vaccine market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Orally Administered Vaccine Market by Company

Lanzhou Institute

Sanofi

Merck

GSK

Tiantan Biological

Valneva

Vabiotech

Shanghai United Cell

Serum Institute

PaxVax

Panacea Biotec Ltd

Halfkin Bio-Pharmaceuticals

EuBiologics

Bio-Med

Bibcol

Orally Administered Vaccine Segment by Type

Rotavirus Vaccine

Oral Polio Vaccine

Cholera Vaccine

Other

Orally Administered Vaccine Segment by Application

Public

Private

Orally Administered Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Orally Administered Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Orally Administered Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Orally Administered Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Orally Administered Vaccine manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Orally Administered Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Rotavirus Vaccine Table 2. Major Company of Oral Polio Vaccine Table 3. Major Company of Cholera Vaccine Table 4. Major Company of Other Table 5. Global Orally Administered Vaccine Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 6. Global Orally Administered Vaccine Sales by Type (2021-2026) & (k units) Table 7. Global Orally Administered Vaccine Sales Market Share in Volume by Type (2021-2026) Table 8. Global Orally Administered Vaccine Sales by Type (2021-2026) & (US$ Million) Table 9. Global Orally Administered Vaccine Sales Market Share in Value by Type (2021-2026) Table 10. Global Orally Administered Vaccine Price by Type (2021-2026) & (US$/unit) Table 11. Global Orally Administered Vaccine Sales by Type (2027-2032) & (k units) Table 12. Global Orally Administered Vaccine Sales Market Share in Volume by Type (2027-2032) Table 13. Global Orally Administered Vaccine Sales by Type (2027-2032) & (US$ Million) Table 14. Global Orally Administered Vaccine Sales Market Share in Value by Type (2027-2032) Table 15. Global Orally Administered Vaccine Price by Type (2027-2032) & (US$/unit) Table 16. North America Orally Administered Vaccine Sales by Type (2021-2026) & (k units) Table 17. North America Orally Administered Vaccine Sales by Type (2021-2026) & (US$ Million) Table 18. Europe Orally Administered Vaccine Sales by Type (2021-2026) & (k units) Table 19. Europe Orally Administered Vaccine Sales by Type (2021-2026) & (US$ Million) Table 20. Asia-Pacific Orally Administered Vaccine Sales by Type (2021-2026) & (k units) Table 21. Asia-Pacific Orally Administered Vaccine Sales by Type (2021-2026) & (US$ Million) Table 22. Latin America Orally Administered Vaccine Sales by Type (2021-2026) & (k units) Table 23. Latin America Orally Administered Vaccine Sales by Type (2021-2026) & (US$ Million) Table 24. Middle East and Africa Orally Administered Vaccine Sales by Type (2021-2026) & (k units) Table 25. Middle East and Africa Orally Administered Vaccine Sales by Type (2021-2026) & (US$ Million) Table 26. Orally Administered Vaccine Industry Trends Table 27. Orally Administered Vaccine Industry Drivers Table 28. Orally Administered Vaccine Industry Opportunities and Challenges Table 29. Orally Administered Vaccine Industry Restraints Table 30. Global Orally Administered Vaccine Sales Revenue by Company (US$ Million) & (2021-2026) Table 31. Global Orally Administered Vaccine Revenue Market Share by Company (2021-2026) Table 32. Global Orally Administered Vaccine Sales by Company (2021-2026) & (k units) Table 33. Global Orally Administered Vaccine Sales Share by Company (2021-2026) Table 34. Global Orally Administered Vaccine Market Price by Company (2021-2026) & (US$/unit) Table 35. Global Orally Administered Vaccine Industry Company Ranking, 2024 VS 2025 VS 2026 Table 36. Global Orally Administered Vaccine Major Company Production Sites and Headquarters Table 37. Global Orally Administered Vaccine Company, Product Type & Application Table 38. Global Orally Administered Vaccine Company Establishment Date Table 39. Global Company Market Concentration Ratio (CR5 and HHI) Table 40. Global Orally Administered Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 41. Global Orally Administered Vaccine Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 42. Global Orally Administered Vaccine Sales by Region (2021-2026) & (k units) Table 43. Global Orally Administered Vaccine Sales Market Share in Volume by Region (2021-2026) Table 44. Global Orally Administered Vaccine Sales by Region (2021-2026) & (US$ Million) Table 45. Global Orally Administered Vaccine Sales Market Share in Value by Region (2021-2026) Table 46. Global Orally Administered Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 47. Global Orally Administered Vaccine Sales by Region (2027-2032) & (k units) Table 48. Global Orally Administered Vaccine Sales Market Share in Volume by Region (2027-2032) Table 49. Global Orally Administered Vaccine Sales by Region (2027-2032) & (US$ Million) Table 50. Global Orally Administered Vaccine Sales Market Share in Value by Region (2027-2032) Table 51. Global Orally Administered Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2027-2032) Table 52. Global Orally Administered Vaccine Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 53. Global Orally Administered Vaccine Sales by Application (2021-2026) & (k units) Table 54. Global Orally Administered Vaccine Sales Market Share in Volume by Application (2021-2026) Table 55. Global Orally Administered Vaccine Sales by Application (2021-2026) & (US$ Million) Table 56. Global Orally Administered Vaccine Sales Market Share in Value by Application (2021-2026) Table 57. Global Orally Administered Vaccine Price by Application (2021-2026) & (US$/unit) Table 58. Global Orally Administered Vaccine Sales by Application (2027-2032) & (k units) Table 59. Global Orally Administered Vaccine Sales Market Share in Volume by Application (2027-2032) Table 60. Global Orally Administered Vaccine Sales by Application (2027-2032) & (US$ Million) Table 61. Global Orally Administered Vaccine Sales Market Share in Value by Application (2027-2032) Table 62. Global Orally Administered Vaccine Price by Application (2027-2032) & (US$/unit) Table 63. North America Orally Administered Vaccine Sales by Application (2021-2026) & (k units) Table 64. North America Orally Administered Vaccine Sales by Application (2021-2026) & (US$ Million) Table 65. Europe Orally Administered Vaccine Sales by Application (2021-2026) & (k units) Table 66. Europe Orally Administered Vaccine Sales by Application (2021-2026) & (US$ Million) Table 67. Asia-Pacific Orally Administered Vaccine Sales by Application (2021-2026) & (k units) Table 68. Asia-Pacific Orally Administered Vaccine Sales by Application (2021-2026) & (US$ Million) Table 69. Latin America Orally Administered Vaccine Sales by Application (2021-2026) & (k units) Table 70. Latin America Orally Administered Vaccine Sales by Application (2021-2026) & (US$ Million) Table 71. Middle East and Africa Orally Administered Vaccine Sales by Application (2021-2026) & (k units) Table 72. Middle East and Africa Orally Administered Vaccine Sales by Application (2021-2026) & (US$ Million) Table 73. Lanzhou Institute Company Information Table 74. Lanzhou Institute Business Overview Table 75. Lanzhou Institute Orally Administered Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Lanzhou Institute Orally Administered Vaccine Product Portfolio Table 77. Lanzhou Institute Recent Development Table 78. Sanofi Company Information Table 79. Sanofi Business Overview Table 80. Sanofi Orally Administered Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Sanofi Orally Administered Vaccine Product Portfolio Table 82. Sanofi Recent Development Table 83. Merck Company Information Table 84. Merck Business Overview Table 85. Merck Orally Administered Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Merck Orally Administered Vaccine Product Portfolio Table 87. Merck Recent Development Table 88. GSK Company Information Table 89. GSK Business Overview Table 90. GSK Orally Administered Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. GSK Orally Administered Vaccine Product Portfolio Table 92. GSK Recent Development Table 93. Tiantan Biological Company Information Table 94. Tiantan Biological Business Overview Table 95. Tiantan Biological Orally Administered Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. Tiantan Biological Orally Administered Vaccine Product Portfolio Table 97. Tiantan Biological Recent Development Table 98. Valneva Company Information Table 99. Valneva Business Overview Table 100. Valneva Orally Administered Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. Valneva Orally Administered Vaccine Product Portfolio Table 102. Valneva Recent Development Table 103. Vabiotech Company Information Table 104. Vabiotech Business Overview Table 105. Vabiotech Orally Administered Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 106. Vabiotech Orally Administered Vaccine Product Portfolio Table 107. Vabiotech Recent Development Table 108. Shanghai United Cell Company Information Table 109. Shanghai United Cell Business Overview Table 110. Shanghai United Cell Orally Administered Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 111. Shanghai United Cell Orally Administered Vaccine Product Portfolio Table 112. Shanghai United Cell Recent Development Table 113. Serum Institute Company Information Table 114. Serum Institute Business Overview Table 115. Serum Institute Orally Administered Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 116. Serum Institute Orally Administered Vaccine Product Portfolio Table 117. Serum Institute Recent Development Table 118. PaxVax Company Information Table 119. PaxVax Business Overview Table 120. PaxVax Orally Administered Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 121. PaxVax Orally Administered Vaccine Product Portfolio Table 122. PaxVax Recent Development Table 123. Panacea Biotec Ltd Company Information Table 124. Panacea Biotec Ltd Business Overview Table 125. Panacea Biotec Ltd Orally Administered Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 126. Panacea Biotec Ltd Orally Administered Vaccine Product Portfolio Table 127. Panacea Biotec Ltd Recent Development Table 128. Halfkin Bio-Pharmaceuticals Company Information Table 129. Halfkin Bio-Pharmaceuticals Business Overview Table 130. Halfkin Bio-Pharmaceuticals Orally Administered Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 131. Halfkin Bio-Pharmaceuticals Orally Administered Vaccine Product Portfolio Table 132. Halfkin Bio-Pharmaceuticals Recent Development Table 133. EuBiologics Company Information Table 134. EuBiologics Business Overview Table 135. EuBiologics Orally Administered Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 136. EuBiologics Orally Administered Vaccine Product Portfolio Table 137. EuBiologics Recent Development Table 138. Bio-Med Company Information Table 139. Bio-Med Business Overview Table 140. Bio-Med Orally Administered Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 141. Bio-Med Orally Administered Vaccine Product Portfolio Table 142. Bio-Med Recent Development Table 143. Bibcol Company Information Table 144. Bibcol Business Overview Table 145. Bibcol Orally Administered Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 146. Bibcol Orally Administered Vaccine Product Portfolio Table 147. Bibcol Recent Development Table 148. North America Orally Administered Vaccine Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 149. North America Orally Administered Vaccine Sales by Country (2021-2026) & (k units) Table 150. North America Orally Administered Vaccine Sales Market Share by Country (2021-2026) Table 151. North America Orally Administered Vaccine Sales Forecast by Country (2027-2032) & (k units) Table 152. North America Orally Administered Vaccine Sales Market Share Forecast by Country (2027-2032) Table 153. North America Orally Administered Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 154. North America Orally Administered Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 155. North America Orally Administered Vaccine Market Share by Country (2021-2026) Table 156. North America Orally Administered Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 157. North America Orally Administered Vaccine Market Share Forecast by Country (2027-2032) Table 158. Europe Orally Administered Vaccine Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 159. Europe Orally Administered Vaccine Sales by Country (2021-2026) & (k units) Table 160. Europe Orally Administered Vaccine Sales Market Share by Country (2021-2026) Table 161. Europe Orally Administered Vaccine Sales Forecast by Country (2027-2032) & (k units) Table 162. Europe Orally Administered Vaccine Sales Market Share Forecast by Country (2027-2032) Table 163. Europe Orally Administered Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 164. Europe Orally Administered Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 165. Europe Orally Administered Vaccine Market Share by Country (2021-2026) Table 166. Europe Orally Administered Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 167. Europe Orally Administered Vaccine Market Share Forecast by Country (2027-2032) Table 168. Asia-Pacific Orally Administered Vaccine Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 169. Asia-Pacific Orally Administered Vaccine Sales by Country (2021-2026) & (k units) Table 170. Asia-Pacific Orally Administered Vaccine Sales Market Share by Country (2021-2026) Table 171. Asia-Pacific Orally Administered Vaccine Sales Forecast by Country (2027-2032) & (k units) Table 172. Asia-Pacific Orally Administered Vaccine Sales Market Share Forecast by Country (2027-2032) Table 173. Asia-Pacific Orally Administered Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 174. Asia-Pacific Orally Administered Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 175. Asia-Pacific Orally Administered Vaccine Market Share by Country (2021-2026) Table 176. Asia-Pacific Orally Administered Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 177. Asia-Pacific Orally Administered Vaccine Market Share Forecast by Country (2027-2032) Table 178. Latin America Orally Administered Vaccine Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 179. Latin America Orally Administered Vaccine Sales by Country (2021-2026) & (k units) Table 180. Latin America Orally Administered Vaccine Sales Market Share by Country (2021-2026) Table 181. Latin America Orally Administered Vaccine Sales Forecast by Country (2027-2032) & (k units) Table 182. Latin America Orally Administered Vaccine Sales Market Share Forecast by Country (2027-2032) Table 183. Latin America Orally Administered Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 184. Latin America Orally Administered Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 185. Latin America Orally Administered Vaccine Market Share by Country (2021-2026) Table 186. Latin America Orally Administered Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 187. Latin America Orally Administered Vaccine Market Share Forecast by Country (2027-2032) Table 188. Middle East and Africa Orally Administered Vaccine Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 189. Middle East and Africa Orally Administered Vaccine Sales by Country (2021-2026) & (k units) Table 190. Middle East and Africa Orally Administered Vaccine Sales Market Share by Country (2021-2026) Table 191. Middle East and Africa Orally Administered Vaccine Sales Forecast by Country (2027-2032) & (k units) Table 192. Middle East and Africa Orally Administered Vaccine Sales Market Share Forecast by Country (2027-2032) Table 193. Middle East and Africa Orally Administered Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 194. Middle East and Africa Orally Administered Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 195. Middle East and Africa Orally Administered Vaccine Market Share by Country (2021-2026) Table 196. Middle East and Africa Orally Administered Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 197. Middle East and Africa Orally Administered Vaccine Market Share Forecast by Country (2027-2032) Table 198. Key Raw Materials Table 199. Raw Materials Key Suppliers Table 200. Orally Administered Vaccine Distributors List Table 201. Orally Administered Vaccine Customers List Table 202. Research Programs/Design for This Report Table 203. Authors List of This Report Table 204. Secondary Sources Table 205. Primary Sources List of Figures Figure 1. Orally Administered Vaccine Image Figure 2. Global Orally Administered Vaccine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Orally Administered Vaccine Market Size (2021-2032) & (US$ Million) Figure 4. Global Orally Administered Vaccine Sales (2021-2032) & (k units) Figure 5. Rotavirus Vaccine Image Figure 6. Global Rotavirus Vaccine Sales YoY Growth (2021-2032) & (k units) Figure 7. Oral Polio Vaccine Image Figure 8. Global Oral Polio Vaccine Sales YoY Growth (2021-2032) & (k units) Figure 9. Cholera Vaccine Image Figure 10. Global Cholera Vaccine Sales YoY Growth (2021-2032) & (k units) Figure 11. Other Image Figure 12. Global Other Sales YoY Growth (2021-2032) & (k units) Figure 13. Global Orally Administered Vaccine Market Size Overview by Type (2021-2032) & (US$ Million) Figure 14. Global Orally Administered Vaccine Market Share by Type 2025 VS 2032 Figure 15. North America Orally Administered Vaccine Sales Market Share in Volume by Type in 2025 Figure 16. North America Orally Administered Vaccine Sales Market Share in Value by Type in 2025 Figure 17. Europe Orally Administered Vaccine Sales Market Share in Volume by Type in 2025 Figure 18. Europe Orally Administered Vaccine Sales Market Share in Value by Type in 2025 Figure 19. Asia-Pacific Orally Administered Vaccine Sales Market Share in Volume by Type in 2025 Figure 20. Asia-Pacific Orally Administered Vaccine Sales Market Share in Value by Type in 2025 Figure 21. Latin America Orally Administered Vaccine Sales Market Share in Volume by Type in 2025 Figure 22. Latin America Orally Administered Vaccine Sales Market Share in Value by Type in 2025 Figure 23. Middle East and Africa Orally Administered Vaccine Sales Market Share in Volume by Type in 2025 Figure 24. Middle East and Africa Orally Administered Vaccine Sales Market Share in Value by Type in 2025 Figure 25. Global Top 5 and 10 Orally Administered Vaccine Players Market Share by Revenue in 2025 Figure 26. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Public Image Figure 28. Global Public Sales YoY Growth (2021-2032) & (k units) Figure 29. Private Image Figure 30. Global Private Sales YoY Growth (2021-2032) & (k units) Figure 31. Global Orally Administered Vaccine Market Size Overview by Application (2021-2032) & (US$ Million) Figure 32. Global Orally Administered Vaccine Market Share by Application 2025 VS 2032 Figure 33. North America Orally Administered Vaccine Sales Market Share in Volume by Application in 2025 Figure 34. North America Orally Administered Vaccine Sales Market Share in Value by Application in 2025 Figure 35. Europe Orally Administered Vaccine Sales Market Share in Volume by Application in 2025 Figure 36. Europe Orally Administered Vaccine Sales Market Share in Value by Application in 2025 Figure 37. Asia-Pacific Orally Administered Vaccine Sales Market Share in Volume by Application in 2025 Figure 38. Asia-Pacific Orally Administered Vaccine Sales Market Share in Value by Application in 2025 Figure 39. Latin America Orally Administered Vaccine Sales Market Share in Volume by Application in 2025 Figure 40. Latin America Orally Administered Vaccine Sales Market Share in Value by Application in 2025 Figure 41. Middle East and Africa Orally Administered Vaccine Sales Market Share in Volume by Application in 2025 Figure 42. Middle East and Africa Orally Administered Vaccine Sales Market Share in Value by Application in 2025 Figure 43. North America Orally Administered Vaccine Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 44. North America Orally Administered Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 45. North America Orally Administered Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. North America Orally Administered Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Orally Administered Vaccine Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 48. Europe Orally Administered Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Orally Administered Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Europe Orally Administered Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Orally Administered Vaccine Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 52. Asia-Pacific Orally Administered Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Orally Administered Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Asia-Pacific Orally Administered Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Orally Administered Vaccine Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 56. Latin America Orally Administered Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Orally Administered Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Latin America Orally Administered Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Orally Administered Vaccine Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 60. Middle East and Africa Orally Administered Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Orally Administered Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Middle East and Africa Orally Administered Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Orally Administered Vaccine Value Chain Figure 64. Key Raw Materials Price Figure 65. Manufacturing Cost Structure Figure 66. Orally Administered Vaccine Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Rotavirus Vaccine
  • Oral Polio Vaccine
  • Cholera Vaccine
  • Other
Applications
  • Public
  • Private
Companies covered
  • Lanzhou Institute
  • Sanofi
  • Merck
  • GSK
  • Tiantan Biological
  • Valneva
  • Vabiotech
  • Shanghai United Cell
  • Serum Institute
  • PaxVax
  • Panacea Biotec Ltd
  • Halfkin Bio-Pharmaceuticals
  • EuBiologics
  • Bio-Med
  • Bibcol

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Orally Administered Vaccine Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Orally Administered Vaccine Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Orally Administered Vaccine Market by Type
  6. 1.3.1 Rotavirus Vaccine
  7. 1.3.2 Oral Polio Vaccine
  8. 1.3.3 Cholera Vaccine
  9. 1.3.4 Other
  10. 1.4 Global Orally Administered Vaccine Market Size by Type
  11. 1.4.1 Global Orally Administered Vaccine Market Size Overview by Type (2021-2032)
  12. 1.4.2 Global Orally Administered Vaccine Historic Market Size Review by Type (2021-2026)
  13. 1.4.3 Global Orally Administered Vaccine Forecasted Market Size by Type (2027-2032)
  14. 1.5 Key Regions Market Size by Type
  15. 1.5.1 North America Orally Administered Vaccine Sales Breakdown by Type (2021-2026)
  16. 1.5.2 Europe Orally Administered Vaccine Sales Breakdown by Type (2021-2026)
  17. 1.5.3 Asia-Pacific Orally Administered Vaccine Sales Breakdown by Type (2021-2026)
  18. 1.5.4 South America Orally Administered Vaccine Sales Breakdown by Type (2021-2026)
  19. 1.5.5 Middle East and Africa Orally Administered Vaccine Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Orally Administered Vaccine Industry Trends
  2. 2.2 Orally Administered Vaccine Industry Drivers
  3. 2.3 Orally Administered Vaccine Industry Opportunities and Challenges
  4. 2.4 Orally Administered Vaccine Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Orally Administered Vaccine Revenue (2021-2026)
  2. 3.2 Global Top Players by Orally Administered Vaccine Sales (2021-2026)
  3. 3.3 Global Top Players by Orally Administered Vaccine Price (2021-2026)
  4. 3.4 Global Orally Administered Vaccine Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Orally Administered Vaccine Major Company Production Sites & Headquarters
  6. 3.6 Global Orally Administered Vaccine Company, Product Type & Application
  7. 3.7 Global Orally Administered Vaccine Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Orally Administered Vaccine Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Orally Administered Vaccine Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Orally Administered Vaccine Tier 1, Tier 2, and Tier 3
4 Orally Administered Vaccine Regional Status and Outlook
  1. 4.1 Global Orally Administered Vaccine Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Orally Administered Vaccine Historic Market Size by Region
  3. 4.2.1 Global Orally Administered Vaccine Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Orally Administered Vaccine Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Orally Administered Vaccine Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Orally Administered Vaccine Forecasted Market Size by Region
  7. 4.3.1 Global Orally Administered Vaccine Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Orally Administered Vaccine Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Orally Administered Vaccine Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Orally Administered Vaccine by Application
  1. 5.1 Orally Administered Vaccine Market by Application
  2. 5.1.1 Public
  3. 5.1.2 Private
  4. 5.2 Global Orally Administered Vaccine Market Size by Application
  5. 5.2.1 Global Orally Administered Vaccine Market Size Overview by Application (2021-2032)
  6. 5.2.2 Global Orally Administered Vaccine Historic Market Size Review by Application (2021-2026)
  7. 5.2.3 Global Orally Administered Vaccine Forecasted Market Size by Application (2027-2032)
  8. 5.3 Key Regions Market Size by Application
  9. 5.3.1 North America Orally Administered Vaccine Sales Breakdown by Application (2021-2026)
  10. 5.3.2 Europe Orally Administered Vaccine Sales Breakdown by Application (2021-2026)
  11. 5.3.3 Asia-Pacific Orally Administered Vaccine Sales Breakdown by Application (2021-2026)
  12. 5.3.4 South America Orally Administered Vaccine Sales Breakdown by Application (2021-2026)
  13. 5.3.5 Middle East and Africa Orally Administered Vaccine Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Lanzhou Institute
  2. 6.1.1 Lanzhou Institute Company Information
  3. 6.1.2 Lanzhou Institute Business Overview
  4. 6.1.3 Lanzhou Institute Orally Administered Vaccine Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Lanzhou Institute Orally Administered Vaccine Product Portfolio
  6. 6.1.5 Lanzhou Institute Recent Developments
  7. 6.2 Sanofi
  8. 6.2.1 Sanofi Company Information
  9. 6.2.2 Sanofi Business Overview
  10. 6.2.3 Sanofi Orally Administered Vaccine Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Sanofi Orally Administered Vaccine Product Portfolio
  12. 6.2.5 Sanofi Recent Developments
  13. 6.3 Merck
  14. 6.3.1 Merck Company Information
  15. 6.3.2 Merck Business Overview
  16. 6.3.3 Merck Orally Administered Vaccine Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Merck Orally Administered Vaccine Product Portfolio
  18. 6.3.5 Merck Recent Developments
  19. 6.4 GSK
  20. 6.4.1 GSK Company Information
  21. 6.4.2 GSK Business Overview
  22. 6.4.3 GSK Orally Administered Vaccine Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 GSK Orally Administered Vaccine Product Portfolio
  24. 6.4.5 GSK Recent Developments
  25. 6.5 Tiantan Biological
  26. 6.5.1 Tiantan Biological Company Information
  27. 6.5.2 Tiantan Biological Business Overview
  28. 6.5.3 Tiantan Biological Orally Administered Vaccine Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Tiantan Biological Orally Administered Vaccine Product Portfolio
  30. 6.5.5 Tiantan Biological Recent Developments
  31. 6.6 Valneva
  32. 6.6.1 Valneva Company Information
  33. 6.6.2 Valneva Business Overview
  34. 6.6.3 Valneva Orally Administered Vaccine Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Valneva Orally Administered Vaccine Product Portfolio
  36. 6.6.5 Valneva Recent Developments
  37. 6.7 Vabiotech
  38. 6.7.1 Vabiotech Company Information
  39. 6.7.2 Vabiotech Business Overview
  40. 6.7.3 Vabiotech Orally Administered Vaccine Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Vabiotech Orally Administered Vaccine Product Portfolio
  42. 6.7.5 Vabiotech Recent Developments
  43. 6.8 Shanghai United Cell
  44. 6.8.1 Shanghai United Cell Company Information
  45. 6.8.2 Shanghai United Cell Business Overview
  46. 6.8.3 Shanghai United Cell Orally Administered Vaccine Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Shanghai United Cell Orally Administered Vaccine Product Portfolio
  48. 6.8.5 Shanghai United Cell Recent Developments
  49. 6.9 Serum Institute
  50. 6.9.1 Serum Institute Company Information
  51. 6.9.2 Serum Institute Business Overview
  52. 6.9.3 Serum Institute Orally Administered Vaccine Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Serum Institute Orally Administered Vaccine Product Portfolio
  54. 6.9.5 Serum Institute Recent Developments
  55. 6.10 PaxVax
  56. 6.10.1 PaxVax Company Information
  57. 6.10.2 PaxVax Business Overview
  58. 6.10.3 PaxVax Orally Administered Vaccine Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 PaxVax Orally Administered Vaccine Product Portfolio
  60. 6.10.5 PaxVax Recent Developments
  61. 6.11 Panacea Biotec Ltd
  62. 6.11.1 Panacea Biotec Ltd Company Information
  63. 6.11.2 Panacea Biotec Ltd Business Overview
  64. 6.11.3 Panacea Biotec Ltd Orally Administered Vaccine Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Panacea Biotec Ltd Orally Administered Vaccine Product Portfolio
  66. 6.11.5 Panacea Biotec Ltd Recent Developments
  67. 6.12 Halfkin Bio-Pharmaceuticals
  68. 6.12.1 Halfkin Bio-Pharmaceuticals Company Information
  69. 6.12.2 Halfkin Bio-Pharmaceuticals Business Overview
  70. 6.12.3 Halfkin Bio-Pharmaceuticals Orally Administered Vaccine Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Halfkin Bio-Pharmaceuticals Orally Administered Vaccine Product Portfolio
  72. 6.12.5 Halfkin Bio-Pharmaceuticals Recent Developments
  73. 6.13 EuBiologics
  74. 6.13.1 EuBiologics Company Information
  75. 6.13.2 EuBiologics Business Overview
  76. 6.13.3 EuBiologics Orally Administered Vaccine Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 EuBiologics Orally Administered Vaccine Product Portfolio
  78. 6.13.5 EuBiologics Recent Developments
  79. 6.14 Bio-Med
  80. 6.14.1 Bio-Med Company Information
  81. 6.14.2 Bio-Med Business Overview
  82. 6.14.3 Bio-Med Orally Administered Vaccine Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Bio-Med Orally Administered Vaccine Product Portfolio
  84. 6.14.5 Bio-Med Recent Developments
  85. 6.15 Bibcol
  86. 6.15.1 Bibcol Company Information
  87. 6.15.2 Bibcol Business Overview
  88. 6.15.3 Bibcol Orally Administered Vaccine Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Bibcol Orally Administered Vaccine Product Portfolio
  90. 6.15.5 Bibcol Recent Developments
7 North America by Country
  1. 7.1 North America Orally Administered Vaccine Sales by Country
  2. 7.1.1 North America Orally Administered Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Orally Administered Vaccine Sales by Country (2021-2026)
  4. 7.1.3 North America Orally Administered Vaccine Sales Forecast by Country (2027-2032)
  5. 7.2 North America Orally Administered Vaccine Market Size by Country
  6. 7.2.1 North America Orally Administered Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Orally Administered Vaccine Market Size by Country (2021-2026)
  8. 7.2.3 North America Orally Administered Vaccine Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Orally Administered Vaccine Sales by Country
  2. 8.1.1 Europe Orally Administered Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Orally Administered Vaccine Sales by Country (2021-2026)
  4. 8.1.3 Europe Orally Administered Vaccine Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Orally Administered Vaccine Market Size by Country
  6. 8.2.1 Europe Orally Administered Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Orally Administered Vaccine Market Size by Country (2021-2026)
  8. 8.2.3 Europe Orally Administered Vaccine Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Orally Administered Vaccine Sales by Country
  2. 9.1.1 Asia-Pacific Orally Administered Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Orally Administered Vaccine Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Orally Administered Vaccine Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Orally Administered Vaccine Market Size by Country
  6. 9.2.1 Asia-Pacific Orally Administered Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Orally Administered Vaccine Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Orally Administered Vaccine Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Orally Administered Vaccine Sales by Country
  2. 10.1.1 South America Orally Administered Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Orally Administered Vaccine Sales by Country (2021-2026)
  4. 10.1.3 South America Orally Administered Vaccine Sales Forecast by Country (2027-2032)
  5. 10.2 South America Orally Administered Vaccine Market Size by Country
  6. 10.2.1 South America Orally Administered Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Orally Administered Vaccine Market Size by Country (2021-2026)
  8. 10.2.3 South America Orally Administered Vaccine Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Orally Administered Vaccine Sales by Country
  2. 11.1.1 Middle East and Africa Orally Administered Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Orally Administered Vaccine Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Orally Administered Vaccine Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Orally Administered Vaccine Market Size by Country
  6. 11.2.1 Middle East and Africa Orally Administered Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Orally Administered Vaccine Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Orally Administered Vaccine Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Orally Administered Vaccine Value Chain Analysis
  2. 12.1.1 Orally Administered Vaccine Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Orally Administered Vaccine Production Mode & Process
  7. 12.2 Orally Administered Vaccine Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Orally Administered Vaccine Distributors
  10. 12.2.3 Orally Administered Vaccine Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst